Lambert-Eaton myasthenic syndrome
ICD-10 G73.1 · ICD-11 8C62

Lambert-Eaton Myasthenic Syndrome: What to Do When Azathioprine Fails to Achieve the Lymphocyte Count Target

This protocol addresses the clinical situation in Lambert-Eaton myasthenic syndrome where initial treatment with glucocorticosteroids combined with azathioprine has not achieved its haematological monitoring goal, prompting a structured escalation to an alternative immunosuppressive approach.

Prior Treatment — Escalation Trigger

The previous regimen — glucocorticosteroids combined with azathioprine — failed to achieve the target absolute lymphocyte count of 600–1000/μl during azathioprine therapy. Non-achievement of this monitoring target is the criterion for escalating to this next-line protocol.

Next-Line Approach (Partial Overview)

When azathioprine does not meet the lymphocyte count goal, the next step involves switching to an alternative immunosuppressive agent combined with glucocorticosteroids. Several agents from different pharmacological classes may be considered — the full selection criteria, sequencing, and regimen details are in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

As an alternative to AZA, treatment with MMF, CSA, tacrolimus, or RTX should be considered if appropriate.

DOI: 10.1177/17562864231213240

View source ↗